9VC

9VC is a tech-enabled biopharmaceutical venture firm and company creator focused on the "reincarnation" of clinical-stage drug assets. The firm utilizes its proprietary digital platform, 9xchange (9xc), to identify untapped or undervalued assets and facilitate their transition into new development programs or optimized company structures. By integrating AI and machine learning with an experienced team of industry veterans, 9VC aims to reduce clinical trial risk and bridge the gap between asset identification and commercial realization. The company is currently focused on high-potential programs such as lasofoxifene, a Phase 3 candidate for metastatic breast cancer, and the neurodegenerative therapy ATH-1105. 9VC acts as both a strategic architect and an investor, leveraging its marketplace to create arbitrage value within the biopharma ecosystem.